Naproxcinod review sparks debate over role of off-label promotion in FDA approval decisions
This article was originally published in Scrip
Executive Summary
The recent US FDA advisory panel review of NicOx's anti-inflammatory agent naproxcinod sparked a debate between the agency and its outside experts over whether the potential effects of off-label promotion and literature on unapproved uses should be considered in drug approval decisions.